Celltrion Healthcare
Scope
Date
~
-
Bio & Pharma
Celltrion eyes M&A in Europe, $3.3 bn Zymfentra sales: chairman
WASHINGTON, D.C. – South Korean biosimilar giant Celltrion Inc. is accelerating its push to transform into a novel drug developer, going after...
May 23, 2024 (Gmt+09:00)
-
Bio & Pharma
Celltrion to supply Remsima, Herzuma to Peru
South Korea's Celltrion Inc. announced on Thursday that it secured a contract to supply its biosimilars for autoimmune disease treatment and antican...
May 02, 2024 (Gmt+09:00)
-
Bio & Pharma
Celltrion releases Remsima SC in Denmark
South Korea's Celltrion Inc. announced on Thursday that it released its autoimmune disease treatment Remsima SC (infliximab) in Denmark. Remsima SC ...
Apr 19, 2024 (Gmt+09:00)
-
Bio & Pharma
Korea’s Celltrion, SK Biopharmaceuticals benefit from direct US sales
Celltrion Inc. and SK Biopharmaceuticals Co. are witnessing improving sales revenue and profitability by selling their products through their own ma...
Apr 16, 2024 (Gmt+09:00)
-
Bio & Pharma
Celltrion'a autoimmune disease drug Zymfentra makes US debut
South Korean biopharmaceutical giant Celltrion Inc. said on March 17 that it has launched its new autoimmune disease treatment Zymfentra in the US m...
Mar 18, 2024 (Gmt+09:00)
-
Korean startups
Foreign venture funding for Korean startups picks up
South Korean startups raising funds from overseas venture capital firms nearly doubled in the first two months of this year from a year ago, heighte...
Mar 12, 2024 (Gmt+09:00)
-
Bio & Pharma
Celltrion ships initial supply of Zymfentra to US
South Korea's Celltrion Inc. announced on Wednesday that it shipped the first supply of its subcutaneous injection type of the autoimmune disease tr...
Feb 29, 2024 (Gmt+09:00)
-
Bio & Pharma
Celltrion to deliver three treatments to Peru
South Korea’s Celltrion Inc. announced on Thursday that it will supply three treatments, including its blood cancer drug Truxima (rituximab) t...
Feb 15, 2024 (Gmt+09:00)
-
Bio & Pharma
Celltrion to supply Remsima SC, Yuflyma to Norway
South Korea's Celltrion Inc. announced on Wednesday that it will supply its autoimmune disease treatments Remsima SC (infliximab) and Yuflyma, the...
Feb 07, 2024 (Gmt+09:00)
-
Retail
Lotte to sell 7-Eleven’s ATM unit in Korea for around $38 mn
Lotte Group is set to sell the automated teller machine (ATM) business of Korea Seven Co., the operator of convenience store chain 7-Eleven in South...
Feb 07, 2024 (Gmt+09:00)
-
Bio & Pharma
Kakao launches AI-based blood sugar management solution
South Korea’s Kakao Healthcare Corp. has introduced an artificial intelligence-based blood sugar management solution targeting the global digi...
Feb 01, 2024 (Gmt+09:00)
-
Private equity
Korean LPs seek private equity secondaries amid liquidity crunch
Secondary strategy is South Korean institutional investors’ top pick for private equity investments for two straight years, a survey showed. Man...
Feb 01, 2024 (Gmt+09:00)
-
Economy
Korea needs population growth for sustainability: World Bank chief
World Bank President Ajay Banga said on Thursday that South Korea needs to boost population growth by easing the fierce competition in education and...
Jan 25, 2024 (Gmt+09:00)
-
Bio & Pharma
Celltrion, WuXi XDC to develop new antibody-drug conjugates
South Korea’s Celltrion Inc. has signed a business agreement with China’s WuXi XDC to jointly develop new antibody-drug conjugates (ADC)...
Jan 24, 2024 (Gmt+09:00)
-
Bio & Pharma
Celltrion to export three anticancer drugs to Europe
South Korea’s Celltrion Inc. announced on Thursday that it has secured supply contracts for three anticancer biosimilars in European countries...
Jan 18, 2024 (Gmt+09:00)
-
Bio & Pharma
Celltrion Holdings eyes Nasdaq IPO by early 2025: chairman
South Korean biosimilar giant Celltrion Group is planning to debut on the Nasdaq market by early 2025, founder and Chairman Seo Jung-jin said at the...
Jan 16, 2024 (Gmt+09:00)
-
Bio & Pharma
Celltrion to expand Yuflyma supply network in Europe
South Korea’s Celltrion Inc. announced on Friday that it will supply its biosimilar Yuflyma (active ingredient: adalimumab) for the treatment ...
Jan 12, 2024 (Gmt+09:00)
-
Aerospace & Defense
Boryung, Axiom Space launch joint venture in Korea
Boryung Corp., a South Korean healthcare investment company, said on Thursday it has officially launched a joint venture with Axiom Space, a US comm...
Jan 11, 2024 (Gmt+09:00)
-
Bio & Pharma
Celltrion revises up earnings goals to overtake Amgen
Celltrion Inc., South Korea's leading biosimilar maker, on Wednesday expressed its ambition to join the global top 10 biotech and pharmaceutical com...
Jan 11, 2024 (Gmt+09:00)
-
Bio & Pharma
Celltrion applies for interchangeability of Yuflyma in US
South Korea's Celltrion Inc. announced on Wednesday that it has applied to the US Food and Drug Administration (FDA) for a modified approval to repl...
Jan 10, 2024 (Gmt+09:00)
-
Tech, Media & Telecom
LG to inject $700 million in startups in West Virginia
CHARLESTON, WV – LG Electronics Inc. will form a fund with the State of West Virginia to inject $700 million over the next five years to foste...
Jan 04, 2024 (Gmt+09:00)
-
Korean startups
Digital healthcare, robot, AI chip startups among VCs’ 2024 top picks
Startups that specialize in digital healthcare, robots and artificial intelligence chips are among South Korea-based venture capital firms’ to...
Jan 03, 2024 (Gmt+09:00)
-
Mergers & Acquisitions
Celltrion to sell portfolio of Takeda drugs to CBC Group
South Korea’s Celltrion Inc. will divest of a portfolio of Takeda Pharmaceutical's prescription medicines sold in Asia to CBC Group, a Singapo...
Jan 01, 2024 (Gmt+09:00)
-
Bio & Pharma
Celltrion applies for approval of Xolair biosimilar in Canada
South Korean biopharmaceutical company Celltrion Inc. announced on Wednesday that it has applied for CT-P39, a biosimilar of the treatment of asth...
Dec 27, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion’s Vegzelma listed on US PBM preferred drug list
South Korea's Celltrion Healthcare Co. announced on Tuesday that its anti-cancer biosimilar Vegzelma (active ingredient: bevacizumab) was listed as ...
Dec 12, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion Healthcare's Herzuma selected as funded brand in NZ
Celltrion Healthcare Co. announced on Thursday that its biosimilar anticancer drug Herzuma (active ingredient trastuzumab) for breast and gastr...
Dec 07, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion, Cyron to develop multi-specific antibody new drug
South Korea’s biopharmaceutical company Celltrion Inc. announced on Wednesday that it signed a joint research agreement with domestic startup ...
Dec 06, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion Healthcare's Remsima SC to be launched in US in 2024
Celltrion Healthcare Co. announced on Thursday that its autoimmune disease treatment Zymfentra (the US product name for Remsima SC) is set to be lau...
Nov 30, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion applies for approval in Europe for eye treatment biosimilar
South Korean biopharmaceutical company Celltrion Inc. announced on Friday that it applied for approval from the European Medicines Agency (EMA) for ...
Nov 24, 2023 (Gmt+09:00)
-
Bio & Pharma
SK C&C to promote AI healthcare for brain diseases
South Korea's SK C&C announced on Thursday that it signed a strategic business agreement with Neurophet, a cloud-based AI platform for brain ima...
Nov 23, 2023 (Gmt+09:00)